Actavis has 18 principal global R&D facilities focused on identifying and pursuing global product development opportunities across all three of its core product businesses. Actavis Pharma is currently developing approximately 185 potential products in the U.S.

Research and development activities capitalize on the Company’s expertise in numerous drug delivery technologies, including solid dosage from, oral-controlled and sustained releasesemi-solid, liquid, oral transmucosal, transdermal, gel, injectable, and other drug delivery technologies and the application of these technologies to proprietary drug forms.